Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annu...(l-2 proteins restoringcell death to canc...),Health

Kinase Inhibitors (ABT-869)

Many oncology researchers are currently developing agents that target kinases, a class of enzymes that are often overly activated in cancer cells. Inhibition of the appropriate kinases can suppress tumor growth by cutting off its blood supply.

Discovered by Abbott scientists, ABT-869 is an oral small molecule that provides simultaneously potent and specific inhibition of the VEGFR and PDGFR families that is in Phase I clinical trials for solid tumors and selected hematologic malignancies such as leukemia. Phase II trials for several tumor types began this year.

PARP Inhibitors (ABT-888)

DNA damaging agents remain some of the most successful treatments for cancer. The enzyme Poly(ADP-ribose)polymerase (abbreviated PARP) can help repair DNA damage caused by these agents used to treat cancer and render them ineffective. As PARP activity is often increased in cancer cells, it provides these cells with a survival mechanism.

ABT-888 is an oral PARP-inhibitor developed by Abbott researchers to prevent DNA repair in cancer cells and increase the effectiveness of common cancer therapies such as radiation and alkylating agents.

ABT-888 completed a Phase 0 trial for patients with refractory solid tumors and lymphoid malignancies, and has entered several Phase I trials. Preclinical data indicates ABT-888 has improved the effectiveness of radiation and many types of chemotherapy in animal models of cancer.

About Abbott Oncology

Abbott Oncology is committed to the discovery and development of innovative cancer treatments that enable patients to live longer and healthier lives. Abbott's oncology research is focused on developing more targeted, less toxic therapies than are cu
'/>"/>